Science

An ideal modality for cell depletion.

With high potency and specificity, T cells engagers (TCEs) represent an off-the-shelf therapeutic modality for resetting the immune system by depleting the proinflammatory cells underlying many immune-mediated diseases. Initial data with TCEs demonstrate the potential to achieve  immunological “reset” and induce durable remissions without the need for ongoing immunosuppression.

We plan to evaluate our lead therapeutic candidate, OM336, in a range of IMDs. Behind our lead program, we are advancing a set of discovery programs targeting additional dimensions of B cell biology. These programs probe unique subsets of B cells that may prove key to achieving longer remissions for patients with certain diseases.